Homepage | Lupus Science & Medicine
网页Lupus Science & Medicine® is a global, peer reviewed, open access online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. An official journal of the Lupus Foundation of America (LFA), which is dedicated to advancing the science and medicine of lupus while offering support to ...
网页WangfiH, etfial Lupus Science Medicine 20218e000458 doi101136/lupus-2020-000458 on September 22, 2024 by guest. Protected by copyright.1 Performance of the 2019 EULAR/ACR systemic lupus erythematosus classification criteria in a cohort of patients with biopsy-confirmed
Scoring systemic lupus erythematosus (SLE) disease activity with …
网页Introduction. SLE is a heterogeneous, multisystem autoimmune disease characterised by waxing and waning disease activity over time.1 Accurately measuring lupus disease activity and the changes in disease activity has proven to be a difficult task. This is highlighted by failure of over 20 late phase therapeutic trials to produce interpretable results,2 though recent positive studies of ...
Achieving remission or low disease activity is associated with …
网页Background Remission and low disease activity (LDA) have been proposed as the treatment goals for patients with systemic lupus erythematosus (SLE). Several definitions for each have been proposed in the literature. Objective To assess the impact of remission/LDA according to various definitions on relevant outcomes in patients with SLE. Methods This systematic literature review was conducted ...
Clinical trial outcomes for SLE: what we have and what we need
网页The paradigm of drug approval in SLE currently relies on successful large phase III randomised controlled trials and a set of primary, secondary and additional end points. Taken together, these outcomes offer a nuanced understanding of the efficacy and safety of the investigational agent. In this review, we thoroughly examine the main outcomes used in SLE trials and highlight unmet ...
Sirolimus versus tacrolimus for systemic lupus erythematosus …
网页Objective The effectiveness and safety of sirolimus for SLE treatment have been shown in some uncontrolled studies. However, a comparison of sirolimus with other classic immunosuppressants has not been reported. We conducted the study to compare the effectiveness and safety of sirolimus versus tacrolimus for SLE treatment. Methods A real-world cohort study was conducted. Patients with ...
网页TummalaR, et−al Lupus Science Medicine 20218e000464 doi101136lupus2020000464 1 Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials Raj Tummala,1 Gabriel Abreu,2 Lilia Pineda,1 M Alex Michaels,1 Rubana N Kalyani,1 Richard A Furie,3 Eric F Morand4 To cite: Tummala R, Abreu G, Pineda L, et al.Safety profile
Authors | Lupus Science & Medicine - Lupus Science & …
网页Lupus Science & Medicine® is an open access journal and levies an Article Processing Charge (APC) of GBP 2,163 (exclusive of VAT for UK and EU authors). The APC for a Protocol, Brief communication or Letter is 1,082 GBP. There are no submission, colour or page charges. There is a 25% discount for articles where the corresponding author has ...
网页Thanoua etΔal Lupus Science Medicine 216e365 doi11136lupus21365 1 Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures Aikaterini Thanou , 1 Judith A James,1,2 Cristina Arriens , 1 Teresa Aberle,1 Eliza Chakravarty,1 Joseph Rawdon,1 Stavros Stavrakis,2 Joan T Merrill,1 …
网页CB-CAPs are complement split products bound to blood cells and include C4d bound to B and T cells (BC4d and TC4d, respectively), erythrocytes (EC4d), reticulocytes (RC4d) and platelets (PC4d). CB-CAPs can be quan-tified by flow cytometry. Extensive research by several groups has demonstrated that cell-bound C4d and C3d are elevated in patients ...
跳至内容